<DOC>
	<DOCNO>NCT00856869</DOCNO>
	<brief_summary>The study conduct describe compare plasma pharmacokinetics NRL972 administer standard meal fast patient hepatic cirrhosis ( Child-Turcotte-Pugh [ CTP ] class A-C ) , NASH , young elderly healthy male , young elderly healthy female , assess effect liver dysfunction , gender , age prandial intestinal hyperaemia clearance NRL972 . In addition , study provide information safety tolerability repeat intravenous dos NRL972 population .</brief_summary>
	<brief_title>Clearance NRL972 Patients With Cirrhosis , Nonalcoholic Steatohepatitis ( NASH ) Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>General subject 1 . Males female ( female nonchildbearing potential childbearing potential take medically appropriate contraception ) 2 . Caucasian 3 . BMI : 19 34 kg.m2 4 . BW : 45 110 kg 5. willing able provide inform consent Healthy volunteer ( group N ) 6 . Age : 18 40 year ( inclusive ) e.g . &gt; 60 year 7 . Assessed healthy base pre study examination Hepatic cirrhosis 8 . Age : 18 75 year 9. stable compensate liver cirrhosis ( cryptogenic , posthepatic , alcoholic ) histological macroscopic ( e.g . laparascopy , biopsy , ultrasound sonography adequate imaging technique ) confirmation Nonalcoholic steatohepatitis ( NASH ) 10 . Age : 18 75 year 11 . Diagnosis NASH confirm liver biopsy General subject 1 . Previous participation trial 2 . Participant trial last 90 day 3 . Donation blood last 60 day history blood loss exceed 450 mL within last 3 month 4 . History clinically relevant allergy 5 . Uncontrolled diabetes mellitus intolerability Galactose test 6 . Presence acute chronic infection 7 . Resting systolic blood pressure &gt; 160 &lt; 90 mmHg , diastolic blood pressure &gt; 95 &lt; 50 mmHg 8 . Clinically relevant ECGabnormalities , prolong QTc &gt; 450 msec male &gt; 460 msec female particular 9 . Clinically relevant ECGabnormalities constitute contraindication LidocainMEG'Xtest 10 . Positive HIV test 11 . Positive alcohol urine drug test recruitment 12 . Daily use &gt; 30 gr alcohol 13 . Smoking 15 cigarettes/day equivalent tobacco product 14 . Use prohibit medication 15 . Suspicion evidence subject trustworthy reliable 16 . Suspicion evidence subject able make free consent understand information regard General females 17 . Positive pregnancy test 18 . Lactating 19 . Not use appropriate contraception premenopausal woman All healthy subject 20 . Presence history relevant comorbidity ( list past present disease review expert panel ) 21 . Presence relevant abnormality laboratory safety test , especially low haemoglobin , increase liver enzymes , reduce serum creatinine ( laboratory test abnormality review expert panel ) 22 . Positive serology HBsAg , anti HBc anti HCV 23 . History alcohol and/or drug abuse . Patients hepatic disease 24 . Biliary liver cirrhosis 25 . Liver impairment due spaceoccupying process ( e.g . carcinoma ) 26 . State liver transplantation patient schedule liver transplantation 27 . Fluctuating rapidly deteriorate hepatic function 28 . Significant bleed diathesis 29 . Oesophageal bleed within last 8 week study entry 30 . Ascites &gt; 6 L abdominal US 31 . Number Connection test : time connect 25 consecutive number &gt; 30 sec 32 . Presence history relevant comorbidity hepatic disease ( list past present disease review expert panel ) 33 . Clinically relevant abnormal laboratory value associate sufficiently explain exist liver disease ( laboratory test abnormality review expert panel ) 34 . History drug alcohol abuse within 2 month prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>